Columbia’s researchers have opened a trial of a noninvasive, focused ultrasound approach to open the blood-brain barrier, enabling higher concentrations of an effective drug to enter the brain.
In the past decade, physicians have recommended that women undergoing some surgeries have their fallopian tubes removed at the same time to prevent ovarian cancer.
A significantly lower proportion of Hispanic and Black women who underwent screening received 3D mammograms, according to a new study presented at the 2022 San Antonio Breast Cancer Symposium.
Director of the National Cancer Institute, Harold Varmus, MD'66, talked about the challenges and goals of precision medicine's efforts to tackle cancer.
Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care.
The drug Gleevec is well known not only for its effectiveness against leukemia. A similar drug might be able to tame some brain cancers, new research from Columbia University Medical Center has shown.
Two Columbia University Medical Center faculty members were present today when President Obama provided details of the precision medicine initiative he announced during this year’s State of the Union address.
Azra Raza, an internationally known specialist in the blood disorder myelodysplastic syndrome, sees patients who travel from all over the country to receive the latest therapies and to participate in research studies for this relatively rare condition.
Richard D. Carvajal, MD, has been named director of the Experimental Therapeutics/Phase I program and melanoma service in medical oncology at NewYork-Presbyterian/Columbia University Medical Center, effective Nov. 1, 2014.